Challenges in Crohn’s Disease Management after Gastrointestinal Cancer Diagnosis

Fiorillo, Claudio; Schena, Carlo Alberto; Quero, Giuseppe; Laterza, Vito; Pugliese, Daniela; Privitera, Giuseppe; Rosa, Fausto; Schepis, Tommaso; Salvatore, Lisa; Stefano, Brunella Di; Larosa, Luigi; Minordi, Laura Maria; Natale, Luigi; Armuzzi, Alessandro; Alfieri, Sergio

doi:10.3390/cancers13030574

Cited by 9 publications

(5 citation statements)

References 216 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, and despite the content of β-F1-ATPase is not increased in the whole cohort of LUAD studied [20], the analysis revealed that the subgroup of patients bearing carcinomas with the highest content of β-F1-ATPase had a worse prognosis when compared to the low content subgroup of patients [20], in agreement with a previous report [66]. Similar findings have been reported in large cohorts of breast [144] and melanoma [146] patients suggesting that, despite there being an overall limitation of OXPHOS in the carcinomas, mitochondrial bioenergetics is required for metastatic disease and cancer progression (see below) [131,154,155].…”

Section: Atp Synthase and The Bioenergetic Signature Of Cancersupporting

confidence: 89%

The Mitochondrial ATP Synthase/IF1 Axis in Cancer Progression: Targets for Therapeutic Intervention

Domínguez-Zorita

Cuezva

2023

Cancers

View full text Add to dashboard Cite

Cancer poses a significant global health problem with profound personal and economic implications on National Health Care Systems. The reprograming of metabolism is a major trait of the cancer phenotype with a clear potential for developing effective therapeutic strategies to combat the disease. Herein, we summarize the relevant role that the mitochondrial ATP synthase and its physiological inhibitor, ATPase Inhibitory Factor 1 (IF1), play in metabolic reprogramming to an enhanced glycolytic phenotype. We stress that the interplay in the ATP synthase/IF1 axis has additional functional roles in signaling mitohormetic programs, pro-oncogenic or anti-metastatic phenotypes depending on the cell type. Moreover, the same axis also participates in cell death resistance of cancer cells by restrained mitochondrial permeability transition pore opening. We emphasize the relevance of the different post-transcriptional mechanisms that regulate the specific expression and activity of ATP synthase/IF1, to stimulate further investigations in the field because of their potential as future targets to treat cancer. In addition, we review recent findings stressing that mitochondria metabolism is the primary altered target in lung adenocarcinomas and that the ATP synthase/IF1 axis of OXPHOS is included in the most significant signature of metastatic disease. Finally, we stress that targeting mitochondrial OXPHOS in pre-clinical mouse models affords a most effective therapeutic strategy in cancer treatment.

show abstract

Section: Atp Synthase and The Bioenergetic Signature Of Cancersupporting

confidence: 89%

The Mitochondrial ATP Synthase/IF1 Axis in Cancer Progression: Targets for Therapeutic Intervention

Domínguez-Zorita

Cuezva

2023

Cancers

View full text Add to dashboard Cite

show abstract

“…A personal history of colorectal malignancy the risk in persons with ulcerative colitis is raised up by 3.7%, [21] while people with Crohn's disease have a 2.5% greater chance of acquiring colorectal malignancy. [22] The persistent inflammation caused by IBD typically culminates in dysplasia, or abnormal cell development.…”

Section: Resultsmentioning

confidence: 99%

Colorectal Cancer: Accuracy of CT in Thdetermination of Staging and Management

El-Kenawy¹,

Alsaeed²,

Najmi³

et al. 2022

Clin Cancer Investig J

View full text Add to dashboard Cite

Colorectal cancer (CRC) is one of the most common cancers worldwide, CRC is the third furthermost common cancer and the fourth principal reason of cancer-related death. Colorectal cancer incidence varies globally, with developed countries having higher rates than developing countries. Colorectal cancer is associated with a lower socioeconomic status The following databases were searched: PubMed, Science Direct, Web of Science, EBSCO, and the Cochrane Library. Using Rayyan QCRI, included studies were screened by heading and abstract before being subjected to a full-text evaluation. This review investigates the published literature regarding the causes, diagnosis, and management of Colorectal cancer. This study comprised 7 trials with a total of 3,134,223 colorectal cancer patients, Most cases were diagnosed by computed tomography and only one study depended on surgery. The included studies used MRI also. CT defines the staging of CRC as the TNM staging [tumor, nodal, and metastases staging. Understanding the unique gene modifications is widely expected to lead to more accurate and tailored care for persons with polyps and malignancies, driven by molecular characterisation of the individual's colon tumour.

show abstract

“…In general, CD can predispose individuals to various intestinal neoplasms, including colorectal, small intestinal, and anal cancers. Colorectal cancer is the most strongly associated with CD, affecting mainly individuals between 40 and 50 years old who have a history of early onset symptoms[ 132 ]. The chronic inflammatory process in the rectal and colonic mucosa, excessive production of free radicals contributing to deoxyribonucleic acid damage, inactivation of tumor suppressor genes, and individual factors are all related to dysplastic mutations and the development of colorectal carcinoma[ 133 ].…”

Section: Clinical Management Of the Crohn’s Disease Today: How It Does?mentioning

confidence: 99%

Crohn's disease and clinical management today: How it does?

da Silva Júnior,

Apolonio,

de Souza Nascimento

et al. 2023

World J Methodol

View full text Add to dashboard Cite

Crohn’s Disease (CD) is an Inflammatory Bowel Disease and is characterized by an immune-mediated nature. Its etiology results from the interaction between genetic, enviromental and microbial factors. Regarding pathophysiology, it involves high levels of interleukin (IL)-12, IL-17, and Th1 profile, along with loss of tolerance mechanisms, an increase in pro-inflammatory interleukins, beyond the possibility to affect any part of the gastrointestinal tract. Its symptoms include abdominal pain, chronic diarrhea, weight loss, anorexia, and fatigue, as well as blood in the stool or rectum. Additionally, conditions comprising musculoskeletal, cutaneous, ocular, hepatic, and hematological alterations may be associated with this scenario and extra-intestinal presentation, such as erythema nodosum, anterior uveitis, osteoporosis, and arthritis can also occur. Today, clinical history, exams as fecal calprotectin, ileocolonocopy, and capsule endoscopy can be performed in the diagnosis investigation, along with treatments to induce and maintain remission. In this sense, anti-inflammatory drugs, such as corticosteroids, immunomodulators, and biological agents, as well as surgery and non-pharmacological interventions plays a role in its therapy. The aim of this review is to bring more current evidence to clinical management of CD, as well as to briefly discuss aspects of its pathophysiology, surveillance, and associated disorders.

show abstract

Challenges in Crohn’s Disease Management after Gastrointestinal Cancer Diagnosis

Cited by 9 publications

References 216 publications

The Mitochondrial ATP Synthase/IF1 Axis in Cancer Progression: Targets for Therapeutic Intervention

The Mitochondrial ATP Synthase/IF1 Axis in Cancer Progression: Targets for Therapeutic Intervention

Colorectal Cancer: Accuracy of CT in Thdetermination of Staging and Management

Crohn's disease and clinical management today: How it does?

Contact Info

Product

Resources

About